| Primary information |
|---|
| ID | antitb_1917, |
| Name | 27387357 |
| N-Terminal modification | Peptide-2 |
| C-Terminal Modification | GF(A6c)G(A6c)R(A6c)G(A6c)F(A6c)G(A6c)GR(A6c)RRRR |
| Chemical Modification | Acetylation |
| Linear/Cyclic | Amidation |
| Length | A6c = 1-aminocyclohexane carboxylic acid, |
| Chirality | Linear |
| Nature | 19 |
| Source | D |
| Origin | Cationic |
| Species | Synthetic |
| Inhibition Concentration | Mycobacterium tuberculosis |
| In Vitro/ In vivo | Mycobacterium tuberculosis H37Rv |
| Cell Line | MIC = 40.75 μM |
| Inhibition Concentration | In vitro |
| Sequence | 2016 |
| Cytotoxicity | NA |
| In vivo Model | NA |
| Lethal Dose | NA |
| Immune Responce | NA |
| Mechanism of Action | NA |
| Target | NA |
| Combination Therapy | NA |
| Other activities | Cell wall pore formation |
| PMID | NA |
| Year of Publication | Antibacterial against Enterobacter aerogenes, Acinetobacter baumannii, Psuedomonas aeruginosa, Klebsiella pneumoniae, Eenterococcus faecalis, Staphylococcus aureus |
Tertiary Structure
(Technique) | Not Predicted), |
| Primary information |
|---|
| ID | antitb_1928, |
| Name | 27387357 |
| N-Terminal modification | Peptide-2 |
| C-Terminal Modification | GF(A6c)G(A6c)R(A6c)G(A6c)F(A6c)G(A6c)GR(A6c)RRRR |
| Chemical Modification | Acetylation |
| Linear/Cyclic | Amidation |
| Length | A6c = 1-aminocyclohexane carboxylic acid, |
| Chirality | Linear |
| Nature | 19 |
| Source | D |
| Origin | Cationic |
| Species | Synthetic |
| Inhibition Concentration | Mycobacterium tuberculosis |
| In Vitro/ In vivo | Mycobacterium tuberculosis MDR |
| Cell Line | MIC = 40.75 μM |
| Inhibition Concentration | In vitro |
| Sequence | 2016 |
| Cytotoxicity | NA |
| In vivo Model | NA |
| Lethal Dose | NA |
| Immune Responce | NA |
| Mechanism of Action | NA |
| Target | NA |
| Combination Therapy | NA |
| Other activities | Cell wall pore formation |
| PMID | NA |
| Year of Publication | Antibacterial against Enterobacter aerogenes, Acinetobacter baumannii, Psuedomonas aeruginosa, Klebsiella pneumoniae, Eenterococcus faecalis, Staphylococcus aureus |
Tertiary Structure
(Technique) | Not Predicted), |
| Primary information |
|---|
| ID | antitb_1939, |
| Name | 27387357 |
| N-Terminal modification | Peptide-2 |
| C-Terminal Modification | GF(A6c)G(A6c)R(A6c)G(A6c)F(A6c)G(A6c)GR(A6c)RRRR |
| Chemical Modification | Acetylation |
| Linear/Cyclic | Amidation |
| Length | A6c = 1-aminocyclohexane carboxylic acid, |
| Chirality | Linear |
| Nature | 19 |
| Source | D |
| Origin | Cationic |
| Species | Synthetic |
| Inhibition Concentration | Mycobacterium tuberculosis |
| In Vitro/ In vivo | Mycobacterium tuberculosis XDR |
| Cell Line | MIC = 10.19 μM |
| Inhibition Concentration | In vitro |
| Sequence | 2016 |
| Cytotoxicity | NA |
| In vivo Model | NA |
| Lethal Dose | NA |
| Immune Responce | NA |
| Mechanism of Action | NA |
| Target | NA |
| Combination Therapy | NA |
| Other activities | Cell wall pore formation |
| PMID | NA |
| Year of Publication | Antibacterial against Enterobacter aerogenes, Acinetobacter baumannii, Psuedomonas aeruginosa, Klebsiella pneumoniae, Eenterococcus faecalis, Staphylococcus aureus |
Tertiary Structure
(Technique) | Not Predicted), |